Literature DB >> 22833564

NESdb: a database of NES-containing CRM1 cargoes.

Darui Xu1, Nick V Grishin, Yuh Min Chook.   

Abstract

The leucine-rich nuclear export signal (NES) is the only known class of targeting signal that directs macromolecules out of the cell nucleus. NESs are short stretches of 8-15 amino acids with regularly spaced hydrophobic residues that bind the export karyopherin CRM1. NES-containing proteins are involved in numerous cellular and disease processes. We compiled a database named NESdb that contains 221 NES-containing CRM1 cargoes that were manually curated from the published literature. Each NESdb entry is annotated with information about sequence and structure of both the NES and the cargo protein, as well as information about experimental evidence of NES-mapping and CRM1-mediated nuclear export. NESdb will be updated regularly and will serve as an important resource for nuclear export signals. NESdb is freely available to nonprofit organizations at http://prodata.swmed.edu/LRNes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833564      PMCID: PMC3442414          DOI: 10.1091/mbc.E12-01-0045

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


INTRODUCTION

Dynamic nuclear–cytoplasmic trafficking of macromolecules controls many eukaryotic cellular processes, such as gene expression, signal transduction, cell differentiation, and immune response. The karyopherin-β family of transport factors recognizes targeting signals within cargo proteins for transport in and out of the nucleus. Nuclear localization signals direct proteins into the nucleus, and nuclear export signals (NESs) direct proteins into the cytoplasm (reviewed in Görlich and Kutay, 1999; Chook and Blobel, 2001; Conti and Izaurralde, 2001; Weis, 2003; Kutay and Güttinger, 2005; Tran ; Xu ). The leucine-rich or classic NES is the only class of nuclear export signal that has been characterized. An NES is 8–15 amino acids long and contains regularly spaced hydrophobic residues. The name leucine-rich NES was coined because the first signals identified in the HIV-1 Rev and PKIα proteins are enriched with leucine residues (Fischer ; Meyer and Malim, 1994; Wen ). Since then, many more NES-containing proteins have been identified, and mutagenesis and computational analyses have shown the NES sequences to be more diverse and conform to the loose consensus sequence φ-X2-3-φ-X2-3-φ-X-φ, where φ is L, V, I, F, or M and X is any amino acid (Bogerd ; Henderson and Eleftheriou, 2000; Engelsma ; la Cour ; Kutay and Güttinger, 2005). The NES is recognized by the export karyopherin CRM1, which is also known as exportin 1 (Fornerod ; Fukuda ; Neville ; Ossareh-Nazari ; Richards ; Stade ). Recently published crystal structures of CRM1 bound to several NESs showed that the signals adopt either combined α-helix–loop or all-loop structures that bind in a hydrophobic groove on the convex surface of CRM1 (Dong , b; Monecke ; Güttler ). Leptomycin B (LMB) inhibits nuclear export by forming a covalent bond with Cys528 of human CRM1, which is located in the NES-binding groove, thus blocking access of the NES to its binding site (Kudo ; Dong ; Monecke ). NESs have been identified in >300 proteins with diverse functions, such as transcription factors, cell cycle regulators, ribonucleoprotein complexes, translation factors, and viral proteins (Fischer ; Wen ; Fridell ; Ho ; Murdoch ; Vissinga ). Nuclear export of viral proteins by CRM1 is important for replication of many viruses that cause human diseases. Aberrant mislocalization of cellular CRM1 cargoes also interrupts numerous cellular processes, often resulting in diseases. Therefore controlling CRM1–NES interactions might be a potential therapeutic target for many disease conditions such as cancer and viral infections (Bogerd ; Yi ; Faustino ; Noske ). A database of 80 NESs named NESbase 1.0 was compiled in 2003 (la Cour ). More recently, Fu ) published a list of 70 NES-containing proteins. Here, we present NESdb, an up-to-date and substantially larger NES database with 221 experimentally identified entries. Each entry is annotated with many detailed features related to the sequence, structure, and nuclear export activity of the NESs and cargo proteins. NESdb is a valuable information resource for the biomedical research community to learn about nuclear export signals that have already been identified. Analysis of the sequences and three-dimensional structures of NESs in NESdb and false-positive NESs generated from NESdb revealed some distinguishing features that might be important for the future development of accurate NES prediction algorithms (Xu ).

DATABASE CONTENT AND DEVELOPMENT

NESdb contains 221 entries as of December 2011. Each entry is a protein that contains one or more NESs. All NESs listed in NESdb were experimentally identified and reported in the published literature. Both the PubMed and UniProt databases were searched using keywords “nuclear export signal,” “NES,” and “CRM1” (Jain ; The UniProt Consortium, 2011). The returned literature was examined with the following criteria to identify the existence of an experimentally tested NES: 1) evidence of CRM1-dependent nuclear export, such as binding to CRM1, inhibition by LMB, nuclear retention at nonpermissive temperature in CRM1 temperature-sensitive yeast strains, or competition with other CRM1 cargoes; 2) the presence of a protein segment that matches the traditional NES consensus sequence φ-X2-3-φ-X2-3-φ-X-φ, which can target a reporter protein for nuclear export; and 3) the presence of mutations within the tested NES segment that abolished nuclear export of the full-length protein. All proteins in NESdb meet the first criterion, and many meet all three criteria. The collected information is manually entered into the database. NESdb was implemented as a MySQL database. PHP5 was used to connect to the database and dynamically generate HTML pages. Apache Web server hosted on a Linux cluster was used to serve the database.

DATABASE ACCESS AND USER INTERFACE

The NESdb database is freely available for nonprofit organizations at http://prodata.swmed.edu/LRNes. At this time, NESdb contains 221 experimentally identified CRM1 cargoes reported in the literature. The published literature is searched on a bimonthly basis and NESdb is updated with every 20 new entries. However, many sequences in the genome, especially those in amphipathic helices, match the NES consensus, thus making accurate NES identification difficult. It is likely that some published studies contain mistakenly identified NESs. As a caution to the research community, we separated the 221 proteins in NESdb into two groups. The first group is named “NESs” and contains experimentally identified NESs with no contradicting experimental evidence. The second group is named “NESs in doubt” and contains proteins that were initially reported as NESs but with doubts on their validity cast by subsequent experiments. Clicking the corresponding link on the main page brings up a list of proteins that belongs to each group. The list can be sorted alphabetically by protein names or numerically by protein ID numbers in NESdb. Users are able to positively or negatively flag specific NES-containing proteins on their individual pages. A tally of flags for each protein is displayed next to its name on the list. An entry with many negative flags will be reevaluated and moved to the “NESs in doubt” category or vice versa. The database is also equipped with a search button, which searches the full name, alternative names, and organism of proteins for the keywords. Clicking on a particular protein will load the individual page for the protein. Each entry contains 14 features related to the sequence, structure, and nuclear export activity of the NESs and cargo proteins. A sample page for snurportin 1 (SNUPN) is shown in Figure 1. The NES features include the following:
FIGURE 1:

A sample page from NESdb that shows 7 of the 14 illustrated features of the NES from snurportin 1 (SNUPN). The features not shown include full name, alternative names, organism, three-dimensional structures, comments, references, and a user input form.

Full name: the recommended name in UniProt database for the given protein, along with the link to its entry in UniProt (Jain ; The UniProt Consortium, 2011). Alternative names: other names of the protein that are commonly used in the literature. Organism: the organism of the listed protein. Experimental evidence for CRM1-mediated nuclear export: reported experimental evidence for CRM1-mediated nuclear export. Reports on whether 1) the protein binds CRM1, 2) the protein is retained in the nucleus by LMB, 3) nuclear export of the protein is affected by another CRM1 cargo such as the HIV-Rev protein, or 4) CRM1 is required for nuclear export in digitonin-permeabilization transport assays. All NESdb entries contain experimental evidence for CRM1-mediated nuclear export. Mutations that affect nuclear export: mutations that have been shown to disrupt nuclear export in cells. Mutations that affect CRM1 binding: mutations that have been shown to disrupt in vitro CRM1 binding. Functional export signals: the protein segment that resembles an NES and when fused to a reporter protein can independently target the reporter for nuclear export. Such data define boundaries and sufficiency of the putative minimal NESs. Secondary structure of the export signal: the explicitly denoted, experimentally determined secondary structure for the reported NES. Other residues important for export: residues known to contact CRM1 or shown to affect CRM1 binding or nuclear export but are located outside of the NES segment. This information may be useful since cargoes may bind CRM1 in multipartite manner and contain additional binding epitopes. Sequence: sequence of the full-length protein with the functional NES underlined. Mutations that disrupt nuclear export in cells are highlighted in yellow, mutations that disrupt in vitro CRM1 binding are in red, and other, non-NES residues reported to affect CRM1 binding or nuclear export are in green. There are four tabs associated with the sequence: 1) the sequence in FASTA format (Pearson and Lipman, 1988), 2) conserved domains of the protein obtained from the Conserved Domain Database (Marchler-Bauer ), 3) predicted secondary structure of the protein by PSIPRED (McGuffin ), and 4) conservation scores of the protein calculated by AL2CO (Pei and Grishin, 2001). Three-dimensional structures: links to three-dimensional structures in the Protein Data Bank (PDB), if available. Comments: a short summary of protein functions and experiments related to the identification of its transport signals. References: the literature from which the features were extracted, with links to PubMed. User input: because NESs are easily misidentified, a user input field at the bottom of each entry that allows users to positively or negatively flag the NES after submitting supporting comments/rationales. A sample page from NESdb that shows 7 of the 14 illustrated features of the NES from snurportin 1 (SNUPN). The features not shown include full name, alternative names, organism, three-dimensional structures, comments, references, and a user input form.

CONCLUSION

NESdb will contribute to the understanding of how protein function is controlled by intracellular localization and will serve as a useful resource for the development of inhibitors that target CRM1-mediated nuclear export. NESdb may be used to train and test new NES prediction algorithms to increase the reliability and accuracy of identifying vague and diverse NESs in the genome.
  42 in total

1.  The PSIPRED protein structure prediction server.

Authors:  L J McGuffin; K Bryson; D T Jones
Journal:  Bioinformatics       Date:  2000-04       Impact factor: 6.937

Review 2.  Transport between the cell nucleus and the cytoplasm.

Authors:  D Görlich; U Kutay
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

3.  AL2CO: calculation of positional conservation in a protein sequence alignment.

Authors:  J Pei; N V Grishin
Journal:  Bioinformatics       Date:  2001-08       Impact factor: 6.937

Review 4.  Karyopherins and nuclear import.

Authors:  Y M Chook; G Blobel
Journal:  Curr Opin Struct Biol       Date:  2001-12       Impact factor: 6.809

Review 5.  Nucleocytoplasmic transport enters the atomic age.

Authors:  E Conti; E Izaurralde
Journal:  Curr Opin Cell Biol       Date:  2001-06       Impact factor: 8.382

Review 6.  Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle.

Authors:  Karsten Weis
Journal:  Cell       Date:  2003-02-21       Impact factor: 41.582

7.  Nuclear export of 5S rRNA-containing ribonucleoprotein complexes requires CRM1 and the RanGTPase cycle.

Authors:  Kirstie Murdoch; Susanne Loop; Falko Rudt; Tomas Pieler
Journal:  Eur J Cell Biol       Date:  2002-10       Impact factor: 4.492

8.  NESbase version 1.0: a database of nuclear export signals.

Authors:  Tanja la Cour; Ramneek Gupta; Kristoffer Rapacki; Karen Skriver; Flemming M Poulsen; Søren Brunak
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

9.  Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs.

Authors:  Rui Yi; Hal P Bogerd; Bryan R Cullen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Nmd3p is a Crm1p-dependent adapter protein for nuclear export of the large ribosomal subunit.

Authors:  J H Ho; G Kallstrom; A W Johnson
Journal:  J Cell Biol       Date:  2000-11-27       Impact factor: 10.539

View more
  77 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Authors:  Takahito Miyake; Sunila Pradeep; Sherry Y Wu; Rajesha Rupaimoole; Behrouz Zand; Yunfei Wen; Kshipra M Gharpure; Archana S Nagaraja; Wei Hu; Min Soon Cho; Heather J Dalton; Rebecca A Previs; Morgan L Taylor; Takeshi Hisamatsu; Yu Kang; Tao Liu; Sharon Shacham; Dilara McCauley; David H Hawke; John E Wiktorowicz; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Authors:  Zachary A Hing; Rose Mantel; Kyle A Beckwith; Daphne Guinn; Erich Williams; Lisa L Smith; Katie Williams; Amy J Johnson; Amy M Lehman; John C Byrd; Jennifer A Woyach; Rosa Lapalombella
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 4.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

5.  Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Authors:  Paul M Tyler; Mariah M Servos; Romy C de Vries; Boris Klebanov; Trinayan Kashyap; Sharon Sacham; Yosef Landesman; Michael Dougan; Stephanie K Dougan
Journal:  Mol Cancer Ther       Date:  2017-02-01       Impact factor: 6.261

6.  Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach.

Authors:  Matthias Michalek; Evgeniy S Salnikov; Burkhard Bechinger
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

7.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

8.  XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Authors:  Yan Cheng; Michael P Holloway; Kevin Nguyen; Dilara McCauley; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Rachel A Altura
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

9.  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Authors:  Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2013-04-16       Impact factor: 11.528

10.  Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry.

Authors:  Ketan Thakar; Samir Karaca; Sarah A Port; Henning Urlaub; Ralph H Kehlenbach
Journal:  Mol Cell Proteomics       Date:  2012-12-13       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.